Accessibility Menu
Teva Pharmaceutical Industries logo

Teva Pharmaceutical Industries(OTC) TEVJF

Market Cap$43.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-32%
5 Year+289%
1 Year+158%
1 Month+12%
$37.00
+0.00%
+0.00Today
Teva Pharmaceutical Industries last closing stock price
MetricPriceDate
Last closeUSD 37.002026-08-17
Teva Pharmaceutical Industries stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+30.28%USD 28.402026-08-05
1 month+12.12%USD 33.002026-07-01
3 month+22.56%USD 30.192026-05-19
Year to date+29.33%USD 28.612025-12-29
1 year+158.38%USD 14.322025-08-15
3 year+287.84%USD 9.542023-08-14
5 year+289.47%USD 9.502021-08-17
Since inception-32.48%USD 54.802003-08-12

Teva Pharmaceutical Industries Financials at a Glance

Market Cap

$43.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$17.32B

Net Income (TTM)

$715.90M

EPS (TTM)

$0.60

P/E Ratio

61.69

Dividend

$0.00

Beta (Volatility)

0.10 (Low)

Price

$37.00

Volume

20

Open

$37.00

Previous Close

$37.00

Daily Range

$37.00 - $37.00

52-Week Range

$14.32 - $37.00

Estimated Earnings Date

Nov 11, 2026

TEVJF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical enterprise specializing in the research, production, marketing, and distribution of generic medications and specialized pharmaceutical products. With a strong presence in North America, Europe, and other international markets, Teva offers a diverse range of products aimed at various therapeutic areas.

Products and Services
  • Generic medications across multiple therapeutic areas
  • Specialized pharmaceutical products, including biopharmaceuticals
  • Active pharmaceutical ingredients and various dosage forms
Growth Outlook
  • Recent quarterly revenue reached $4.14 billion, indicating strong market demand
  • Focus on central nervous system and oncology products supports long-term growth
  • Collaborative agreements for long-acting injectables enhance product pipeline
Financial Highlights
  • Trailing twelve months (TTM) revenue of $16.4 billion reflects stable performance
  • Operating income margin of 17.1% demonstrates operational efficiency
  • Net income for Q2 2026 was -$576 million, highlighting recent challenges
Teva Pharmaceutical Industries Limited operates in a competitive landscape, focusing on both generic and specialized pharmaceuticals. The company's extensive product portfolio includes medications for central nervous system disorders, pain management, respiratory conditions, and oncology. Key products such as Copaxone and AJOVY are well-established in their respective markets. The growth outlook for Teva remains promising, driven by a robust pipeline and strategic collaborations. Recent quarterly results indicate a solid revenue base, although challenges in net income reflect ongoing operational hurdles. The company's focus on innovation and expanding its therapeutic offerings positions it well for future growth. Investors may find Teva's diverse product range and strategic initiatives appealing, despite the recent financial challenges. The company's commitment to research and development, along with its established market presence, provides a foundation for potential long-term success.
AI Generated • Aug 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

33,346

CEO

Richard Francis

Website

www.tevapharm.com

Headquarters

Tel Aviv, TA 6944020, IL

TEVJF Financials

Key Financial Metrics (TTM)

Gross Margin

52.46%

Operating Margin

17.11%

Net Income Margin

4.16%

Return on Equity

9.28%

Return on Capital

8.63%

Return on Assets

1.82%

Earnings Yield

1.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$43.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.17B

Volume

20

Avg. Volume

11.254

Financials (TTM)

Gross Profit

$9.08B

Operating Income

$2.60B

EBITDA

$3.28B

Operating Cash Flow

$1.90B

Capital Expenditure

-$550.00M

Free Cash Flow

$1.05B

Cash & ST Invst.

$3.66B

Total Debt

$16.87B

Teva Pharmaceutical Industries Performance Analysis

Teva Pharmaceutical Industries annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 14,914,000,000-5.9%
20232023-12-31USD 15,848,000,0006.3%
20242024-12-31USD 16,510,000,0004.2%
20252025-12-31USD 17,323,000,0004.9%
Teva Pharmaceutical Industries sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.3%
Q42025-12-315.2%
Q12026-03-31-15.5%
Q22026-06-304.0%
Teva Pharmaceutical Industries annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.20N/A
20232023-12-31USD -0.50-77.3%
20242024-12-31USD -1.45190.1%
20252025-12-31USD 1.21N/A
Teva Pharmaceutical Industries sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3054.2%
Q42025-12-3113.5%
Q12026-03-31-26.2%
Q22026-06-30-258.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$4.14B

-0.8%

Gross Profit

$2.15B

+2.4%

Gross Margin

51.98%

N/A

Market Cap

$43.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.29M

N/A

Employees

33,346

N/A

Net Income

-$576.00M

-304.3%

EBITDA

$408.00M

-37.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.66B

+69.1%

Total Debt

$16.87B

-3.7%

Accounts Receivable

$3.49B

-2.0%

Inventory

$3.22B

-7.9%

Long Term Debt

$12.37B

-27.5%

Short Term Debt

$4.50B

+869.8%

Return on Assets

1.82%

N/A

Return on Invested Capital

12.30%

N/A

Free Cash Flow

$307.00M

+134.4%

Operating Cash Flow

$411.00M

+81.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OTSKFOtsuka Holdings Co., Ltd.
$77.53+0.00%
ALPMYAstellas Pharma Inc.
$15.04+0.53%
TRUMFTerumo Corporation
$16.48+0.00%
ORINYOrion Oyj
$43.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About TEVJF

What is the current price of Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries is trading at $37.00 per share.

What is the 52-week range for Teva Pharmaceutical Industries?

Over the past 52 weeks, Teva Pharmaceutical Industries has traded between $14.32 and $37.00.

How much debt does Teva Pharmaceutical Industries have?

As of the most recent reporting period, Teva Pharmaceutical Industries reported total debt of $16.87B.

How much cash does Teva Pharmaceutical Industries have on hand?

Teva Pharmaceutical Industries reported $3.66B in cash and cash equivalents in its most recent financial results.

What is Teva Pharmaceutical Industries’s dividend yield?

Teva Pharmaceutical Industries does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services